Search

Your search keyword '"Frietsch, Jochen J."' showing total 39 results
Start Over Author "Frietsch, Jochen J."
39 results on '"Frietsch, Jochen J."'

14. Isolation of Hafnia paralvei co-harbouring blaNDM-1 and blaVIM-1 in a woman who underwent allogeneic hematopoietic stem cell transplantation.

Author

Appel, Tobias Manuel, Stein, Claudia, Brandt, Christian, Rödel, Jürgen, Frietsch, Jochen J., Miethke, Jenny, Hochhaus, Andreas, and Hilgendorf, Inken

Subjects
ANTIMICROBIAL stewardship, COLISTIN, SEQUENCE analysis, ULTRASONIC imaging, CARBAPENEM-resistant bacteria, ENTEROBACTERIACEAE, BETA lactamases, HEMATOPOIETIC stem cell transplantation, DRUG resistance in microorganisms, MICROBIAL sensitivity tests
Abstract

Metallo-β-lactamases (MBL) are a threat to public health, since they dramatically limit the use of β-lactams. We report the isolation of a multidrug-resistant Hafnia paralvei strain from urine and a rectal swab of a female patient after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome. Antimicrobial susceptibility testing yielded resistance to trimethoprim/sulfamethoxazole, colistin, fosfomycin and all β-lactams, except cefiderocol. Whole genome sequencing revealed the presence of plasmid-encoded NDM-1 and VIM-1 carbapenemases. This finding highlights the importance of epidemiological surveillance and new therapeutic options for MBL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany.

Author

Frietsch, Jochen J., Flossdorf, Sarah, Beck, James F., Kröger, Nicolaus, Fleischhauer, Katharina, Dreger, Peter, Schetelig, Johannes, Bornhäuser, Martin, Hochhaus, Andreas, and Hilgendorf, Inken

Subjects
*HEMATOPOIETIC stem cell transplantation, *YOUNG adults, *STEM cell transplantation, *ACHIEVED status, *OLDER patients
Abstract

Summary: Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998–2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event‐free and relapse‐free survival as well as for the cumulative incidences of non‐relapse and therapy‐related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post‐HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort

Author

Brioli, Annamaria, primary, Nägler, Theresa Maria, additional, Yomade, Olaposi, additional, Rüthrich, Maria Madeleine, additional, Scholl, Sebastian, additional, Frietsch, Jochen J., additional, Hilgendorf, Inken, additional, Ernst, Thomas, additional, Sayer, Herbert Gottfried, additional, Hochhaus, Andreas, additional, Mügge, Lars-Olof, additional, and von Lilienfeld-Toal, Marie, additional

Published
2022
Full Text
View/download PDF

21. Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Author

Mühleck, Regina, primary, Scholl, Sebastian, additional, Hilgendorf, Inken, additional, Schrenk, Karin, additional, Hammersen, Jakob, additional, Frietsch, Jochen J., additional, Fleischmann, Maximilian, additional, Sayer, Herbert G., additional, Glaser, Anita, additional, Hochhaus, Andreas, additional, and Schnetzke, Ulf, additional

Published
2021
Full Text
View/download PDF

22. Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.

Author

O'Hagan Henderson, Samantha, Frietsch, Jochen J., Hilgendorf, Inken, Hochhaus, Andreas, Köhne, Claus-Henning, and Casper, Jochen

Subjects
*MYELOPROLIFERATIVE neoplasms, *ACUTE myeloid leukemia, *INFLUENZA, *MYELODYSPLASTIC syndromes, *CYTARABINE, *FLUDARABINE
Abstract

Purpose: Treosulfan and fludarabine (Treo/Flu) were successfully introduced into toxicity-reduced conditioning for SCT. However, the risk of post-SCT relapse remains a matter of concern. We report the results of a novel individual treatment approach with Treo/Flu and cytarabine (Treo/Flu/AraC) conditioning prior to allogeneic SCT in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). Methods: Seventy-seven patients (median age 54 years) at high risk of disease relapse due to unfavorable cytogenetics or failure to achieve complete remission prior to SCT were included. Median follow-up was 3.2 years. Results: The 1-, 2- and 3-year RFS rates were 49.4%, 41.7%, and 37.6% and OS rates were 59.3%, 49.3%, and 45.4%, respectively. Cumulative incidence of NRM was 10% at 100 days, 18.8% at 1 year and 20.1% at 2 years. The cumulative incidence of relapse increased from 31% at 1 year to 38.5% after 3 years. The cumulative incidences of engraftment, chimerism, graft-versus-host disease (GvHD) and toxicities were acceptable and comparable with similar patients conditioned with Treo/Flu or FLAMSA-RIC. Conclusion: In conclusion, Treo/Flu/AraC provides tolerable, feasible, and effective conditioning for patients with AML, MDS or MPN, even in advanced disease states. The incidence of NRM and relapse is acceptable in this heavily pre-treated population with high-risk disease. Future research will aim to confirm these initial findings and include a larger number of participants in a prospective trial. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia

Author

Fleischmann, Maximilian, primary, Schnetzke, Ulf, additional, Frietsch, Jochen J., additional, Sayer, Herbert G., additional, Schrenk, Karin, additional, Hammersen, Jakob, additional, Glaser, Anita, additional, Hilgendorf, Inken, additional, Hochhaus, Andreas, additional, and Scholl, Sebastian, additional

Published
2021
Full Text
View/download PDF

28. Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance

Author

Herrmann, Andreas B., Müller, Martha‐Lena, Orth, Martin F., Müller, Jörg P., Zernecke, Alma, Hochhaus, Andreas, Ernst, Thomas, Butt, Elke, and Frietsch, Jochen J.

Subjects
Receptors, CXCR4, Transcription, Genetic, Cell Survival, LASP1, Cell Degranulation, Gene Knockout Techniques, Adenosine Triphosphate, Cell Movement, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Cell Adhesion, Humans, BCR‐ABL, ddc:610, CML, Protein Kinase Inhibitors, nilotinib, Adaptor Proteins, Signal Transducing, Cell Proliferation, CXCR4, Cell Death, Original Articles, LIM Domain Proteins, Gene Expression Regulation, Neoplastic, Killer Cells, Natural, Cytoskeletal Proteins, Pyrimidines, Treatment Outcome, precursor cells, Drug Resistance, Neoplasm, Protein Biosynthesis, Imatinib Mesylate, Original Article, K562 Cells
Abstract

Chronic myeloid leukaemia (CML) is a clonal myeloproliferative stem cell disorder characterized by the constitutively active BCR‐ABL tyrosine kinase. The LIM and SH3 domain protein 1 (LASP1) has recently been identified as a novel BCR‐ABL substrate and is associated with proliferation, migration, tumorigenesis and chemoresistance in several cancers. Furthermore, LASP1 was shown to bind to the chemokine receptor 4 (CXCR4), thought to be involved in mechanisms of relapse. In order to identify potential LASP1‐mediated pathways and related factors that may help to further eradicate minimal residual disease (MRD), the effect of LASP1 on processes involved in progression and maintenance of CML was investigated. The present data indicate that not only overexpression of CXCR4, but also knockout of LASP1 contributes to proliferation, reduced apoptosis and migration as well as increased adhesive potential of K562 CML cells. Furthermore, LASP1 depletion in K562 CML cells leads to decreased cytokine release and reduced NK cell‐mediated cytotoxicity towards CML cells. Taken together, these results indicate that in CML, reduced levels of LASP1 alone and in combination with high CXCR4 expression may contribute to TKI resistance.

Published
2020

30. Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia

Author

Butt, Elke, primary, Stempfle, Katrin, additional, Lister, Lorenz, additional, Wolf, Felix, additional, Kraft, Marcella, additional, Herrmann, Andreas B., additional, Viciano, Cristina Perpina, additional, Weber, Christian, additional, Hochhaus, Andreas, additional, Ernst, Thomas, additional, Hoffmann, Carsten, additional, Zernecke, Alma, additional, and Frietsch, Jochen J., additional

Published
2020
Full Text
View/download PDF

36. The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm.

Author

O'Hagan Henderson, Samantha, Glaser, Anita, Frietsch, Jochen J., Hochhaus, Andreas, and Hilgendorf, Inken

Subjects
DOWN syndrome, MYELOPROLIFERATIVE neoplasms, MOSAICISM, TRISOMY 18 syndrome, RUNX proteins, ADULTS
Abstract

Dear Editor, Here we report the case of an adult with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) and constitutional trisomy 21 mosaicism as the only identified chromosomal abnormality. This molecular mosaicism was also found in buccal mucosa cells, showing that the patient was a constitutional trisomy 21 mosaic. Although AML with a I GATA1 i mutation has been identified in children with trisomy 21 mosaicism [[9]], this is to our knowledge, the first reported case of an adult without I GATA1 i mutation and with an MDS/MPN and constitutional trisomy 21 mosaicism as the only identified chromosomal abnormality. [Extracted from the article]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results